Sang-Eun Choi1, Mélanie Brignone2, Seong Jin Cho3, Hong Jin Jeon4, Rangrhee Jung5, Rosanne Campbell6, Clément Francois7, Dominique Milea8. 1. a College of Pharmacy , Korea University , Sejong , South Korea. 2. b Lundbeck SAS , Issy-les-Moulineaux , France. 3. c Gil Medical Center , Gachon University , Incheon , South Korea. 4. d School of Medicine , Sungkyunkwan University , Seoul , South Korea. 5. e HyeRang , Seoul , South Korea. 6. f Mapi Group , Uxbridge , UK. 7. g Lundbeck Inc , Deerfield , USA. 8. h Lundbeck Singapore Pte Ltd , Singapore.
Abstract
OBJECTIVE: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. METHODS: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states. RESULTS: Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations. CONCLUSION: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.
OBJECTIVE: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. METHODS: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states. RESULTS:Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations. CONCLUSION:Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDDpatients initiating or switching therapy.
Entities:
Keywords:
Depression; antidepressant; cost-effectiveness; economic; model